New pill could tame hormone disorder Cushing's syndrome
NCT ID NCT05804669
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests an experimental pill called CRN04894 in 18 adults with Cushing's syndrome caused by too much ACTH hormone. The drug works by blocking the receptor that ACTH acts on, aiming to lower cortisol levels and control the disease. The main goals are to check safety and how the body processes the drug, with a secondary look at cortisol changes. Participants must have active Cushing's and may need to stop other treatments briefly before joining.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUSHING DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health (NIH) - National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a Dual-Action pill tame the tumor behind cushing disease?
- Could muscle proteins reveal hidden muscle loss in diabetes and obesity?
- Hidden liver danger in Cushing's syndrome may reverse after cortisol cure
- Cushing's disease study in western france withdrawn before starting
- Scientists investigate adrenal tumors and seek better therapies
- New study tracks hidden heart and bone risks in Cushing's disease